Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Secured overnight financing rate futures plunge as markets bet September is the most likely timing for the first rate hike

Secured overnight financing rate futures plunge as markets bet September is the most likely timing for the first rate hike

汇通财经汇通财经2026/06/05 12:55
Show original
⑴ After the release of the US May nonfarm payroll data, contracts of various maturities for Secured Overnight Financing Rate (SOFR) futures experienced heavy selling, with the red, green, and blue contract packs falling between 6.125 basis points and 8.5 basis points. The white contract pack, which is highly sensitive to Federal Reserve policy, declined by 3.2 basis points.⑵ Based on a 10-day moving average SOFR of 3.61%, the September contract now implies a 68% probability of a 25 basis point rate hike, up from the previous 56%. The December and next March contracts still fully price in one rate hike. The July contract, due to low liquidity, shows a rate hike probability of 40%. Current pricing indicates that the September FOMC meeting remains the most likely timing for the first rate hike.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Competition in US oral weight-loss drugs intensifies! Eli Lilly (LLY.US) Foundayo captures 30% of new patients, narrowing Novo Nordisk's (NVO.US) first-mover advantage

Eli Lilly stated on Monday that its oral weight-loss drug, Foundayo, has captured over 30% of the market share among new patients in the US oral obesity treatment market, narrowing the early lead achieved by Danish competitor Novo Nordisk with its Wegovy oral tablets.

智通财经2026/09/15 03:21
Competition in US oral weight-loss drugs intensifies! Eli Lilly (LLY.US) Foundayo captures 30% of new patients, narrowing Novo Nordisk's (NVO.US) first-mover advantage